{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:16Z","timestamp":1786982836880,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T00:00:00Z","timestamp":1389225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s40618-013-0012-2","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T06:07:17Z","timestamp":1389161237000},"page":"331-338","source":"Crossref","is-referenced-by-count":9,"title":["Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking"],"prefix":"10.1007","volume":"37","author":[{"given":"B.","family":"\u0141abuz-Roszak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pierzcha\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tyrpie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.jacc.2010.04.003","volume":"55","author":"M Pignone","year":"2010","unstructured":"Pignone M, Alberts MJ, Colwell JA et al (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes. JACC 55:2878\u20132886","journal-title":"JACC"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I et al (2008) The prevention of progression of arterial disease and diabetes POPADAD trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease (abstract). BMJ 337:1840","journal-title":"BMJ"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:2134\u20132214","journal-title":"JAMA"},{"key":"12_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1475-2840-8-57","volume":"8","author":"WY Leung","year":"2009","unstructured":"Leung WY, So W, Steward D et al (2009) Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients\u2014a longitudinal observational study. Cardiovasc Diabetol 8:57\u201367","journal-title":"Cardiovasc Diabetol"},{"key":"12_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, Backer G, Gohlke H et al (2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts): European guidelines on cardiovascular disease prevention in clinical practice: executive summary (version 2012). Eur Heart J 33:1635\u20131701","journal-title":"Eur Heart J"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987\u20131003","journal-title":"Eur Heart J"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71\u201386","journal-title":"BMJ"},{"key":"12_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0404.2005.00419.x","volume":"113","author":"J Berrouschot","year":"2006","unstructured":"Berrouschot J, Schwetlick B, von Twickel G et al (2006) Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 113:31\u201335","journal-title":"Acta Neurol Scand"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clineuro.2007.09.005","volume":"110","author":"JI Seok","year":"2008","unstructured":"Seok JI, Joo IS, Yoon JH et al (2008) Can aspirin resistance be clinically predicted in stroke patients? Clin Neurol Neurosurg 110:110\u2013116","journal-title":"Clin Neurol Neurosurg"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jns.2008.10.013","volume":"277","author":"PL Bernstein","year":"2009","unstructured":"Bernstein PL, Jacobson BF, Connor MD, Becker PJ (2009) Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. J Neurol Sci 277:80\u201382","journal-title":"J Neurol Sci"},{"key":"12_CR11","first-page":"727","volume":"118","author":"M Zytkiewicz","year":"2008","unstructured":"Zytkiewicz M, Gielwanowska L, Wojtasinska E, Psuja P, Zawilska K (2008) Resistance to acetylsalicylic acid in patients after ischaemic stroke. Pol Arch Med Wewn 118:727\u2013732","journal-title":"Pol Arch Med Wewn"},{"key":"12_CR12","first-page":"412","volume":"68","author":"M Postula","year":"2010","unstructured":"Postula M, Tarchalska-Krynska B, Filipiak KJ et al (2010) Factors responsible for aspirin resistance\u2014can we identify them? Kardiol Pol 68:412\u2013413","journal-title":"Kardiol Pol"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000147455","volume":"26","author":"V Karepov","year":"2008","unstructured":"Karepov V, Tolpina G, Kuliczkowski W, Serebruany V (2008) Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischaemic stroke. Cerebrovasc Dis 26:272\u2013276","journal-title":"Cerebrovasc Dis"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jocn.2008.01.006","volume":"15","author":"D Bennet","year":"2008","unstructured":"Bennet D, Yan B, Macgregor L, Eccleston D, Davis SM (2008) A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci 15:1204\u20131209","journal-title":"J Clin Neurosci"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH08-01-0056","volume":"100","author":"N Zimmermann","year":"2008","unstructured":"Zimmermann N, Hohlfeld T (2008) Clinical implications of aspirin resistance. Thromb Haemost 100:379\u2013390","journal-title":"Thromb Haemost"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1210\/jc.2009-2392","volume":"95","author":"DT Ertugrul","year":"2010","unstructured":"Ertugrul DT, Tutal E, Yildiz M et al (2010) Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 95:2897\u20132901","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.thromres.2003.12.016","volume":"113","author":"C Watala","year":"2004","unstructured":"Watala C, Golanski J, Pluta J et al (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)\u2014its relation to metabolic control. Thromb Res 113:101\u2013113","journal-title":"Thromb Res"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.pharmthera.2011.01.011","volume":"130","author":"R Fitzgerald","year":"2011","unstructured":"Fitzgerald R, Pirmohamed M (2011) Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Therap 130:213\u2013225","journal-title":"Pharmacol Therap"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jdiacomp.2007.05.002","volume":"22","author":"HW Cohen","year":"2008","unstructured":"Cohen HW, Crandall JP, Hailpern SM, Billett HH (2008) Aspirin resistance associated with HbA1C and obesity in diabetic patients. J Diabetes Complicat 22:224\u2013228","journal-title":"J Diabetes Complicat"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00592-005-0186-y","volume":"42","author":"S Fateh-Moghadam","year":"2005","unstructured":"Fateh-Moghadam S, Plockinger U, Cabeza N et al (2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99\u2013103","journal-title":"Acta Diabetol"},{"key":"12_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.amjcard.2005.09.093","volume":"97","author":"SS Mehta","year":"2006","unstructured":"Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB (2006) Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567\u2013570","journal-title":"Am J Cardiol"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH06-05-0242","volume":"96","author":"O Toth","year":"2006","unstructured":"Toth O, Calatzis A, Penz S, Losonczy H, Siess W (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96:781\u2013788","journal-title":"Thromb Haemost"},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1309\/AJCPTE3K1SGAPOIZ","volume":"131","author":"R Paniccia","year":"2009","unstructured":"Paniccia R, Antonucci E, Maggini N et al (2009) Assessment of platelet function on whole blood by multiplate electrode platelet aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 131:834\u2013842","journal-title":"Am J Clin Pathol"},{"key":"12_CR24","unstructured":"Calatzis A, Spannagl M, Loreth R (2007) Multiplate platelet function analysis\u2014application and interpretation. V2.0\/07.2007. Dynabyte Medical, Monachium 2007"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/09537100600760814","volume":"17","author":"VR Vaidyula","year":"2006","unstructured":"Vaidyula VR, Boden G, Rao AK (2006) Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 17:577\u2013585","journal-title":"Platelets"},{"key":"12_CR26","first-page":"54","volume":"64","author":"B Labuz-Roszak","year":"2010","unstructured":"Labuz-Roszak B, Pierzchala K, Machowska-Majchrzak A, Porosinska A, Wawrzynczyk M (2010) Evaluation of platelet function in patients taking acetylsalicylic acid as a secondary stroke prevention. Ann Acad Med Siles 64:54\u201363","journal-title":"Ann Acad Med Siles"},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","volume":"326","author":"M Friend","year":"2003","unstructured":"Friend M, Vucenik I, Miller M (2003) Platelet responsiveness to aspirin in patients with hyperlipidemia. BMJ 326:82\u201383","journal-title":"BMJ"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/01.CIR.101.10.1206","volume":"101","author":"EH Awtry","year":"2000","unstructured":"Awtry EH, Loscalza J (2000) Aspirin. Circulation 101:1026\u20131218","journal-title":"Circulation"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1055\/s-2007-996108","volume":"23","author":"K Schror","year":"1997","unstructured":"Schror K (1997) Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23:349\u2013356","journal-title":"Semin Thromb Hemost"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","volume":"325","author":"Dutch TIA Trial Study Group","year":"1991","unstructured":"Dutch TIA Trial Study Group (1991) A comparison of two doses of aspirin (30\u00a0mg vs 283\u00a0mg a day) in patients after a transient ischemic attack of minor ischemic stroke. N Engl J Med 325:1261\u20131266","journal-title":"N Engl J Med"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0049-3848(02)00210-4","volume":"107","author":"L Macchi","year":"2002","unstructured":"Macchi L, Christaens L, Brizard A et al (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107:5\u201349","journal-title":"Thromb Res"},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1161\/01.STR.0000106763.46123.F6","volume":"35","author":"MJ Alberts","year":"2004","unstructured":"Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J (2004) Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35:175\u2013178","journal-title":"Stroke"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1467-789X.2011.00930.x","volume":"13","author":"F Santilli","year":"2012","unstructured":"Santilli F, Vazzana N, Liani R, Guagnano MT, Dav\u00ec G (2012) Platelet activation in obesity and metabolic syndrome. Obes Res 13:27\u201342","journal-title":"Obes Res"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1161\/01.CIR.92.9.2432","volume":"92","author":"J Hung","year":"1995","unstructured":"Hung J, Lam JYT, Lacoste L et al (1995) Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92:2432\u20132436","journal-title":"Circulation"},{"key":"12_CR35","first-page":"479","volume":"105","author":"JW Davis","year":"1985","unstructured":"Davis JW, Hartman CR, Lewis HD et al (1985) Cigarette smoking induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 105:479\u2013483","journal-title":"J Lab Clin Med"},{"key":"12_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","volume":"88","author":"PA Gum","year":"2001","unstructured":"Gum PA, Kottke-Marchand K, Poggio ED et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230\u2013235","journal-title":"Am J Cardiol"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1161\/01.CIR.102.9.1007","volume":"102","author":"F Cipollone","year":"2000","unstructured":"Cipollone F, Ciabattoni G, Patrono C et al (2000) Oxidant stress and aspirin-insensitive tromboxane synthesis in severe unstable angina. Circulation 102:1007\u20131013","journal-title":"Circulation"},{"key":"12_CR38","first-page":"313","volume":"40","author":"A Porosi\u0144ska","year":"2006","unstructured":"Porosi\u0144ska A, Pierzcha\u0142a K (2006) Aspirin resistance theory. Neurol Neurochirur Pol 40:313\u2013319","journal-title":"Neurol Neurochirur Pol"},{"key":"12_CR39","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jacc.2003.08.062","volume":"43","author":"FM Pulcinelli","year":"2004","unstructured":"Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43:979\u2013984","journal-title":"J Am Coll Cardiol"},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00001721-200206000-00001","volume":"13","author":"RE Roller","year":"2002","unstructured":"Roller RE, Dorr A, Ulrich S, Pilger E (2002) Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagulat Fibrynol 13:277\u2013281","journal-title":"Blood Coagulat Fibrynol"},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.amjmed.2006.10.021","volume":"120","author":"WH Chen","year":"2007","unstructured":"Chen WH, Cheng X, Lee PY et al (2007) Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120:631\u2013635","journal-title":"Am J Med"},{"key":"12_CR42","first-page":"2677","volume":"92","author":"L Li","year":"2012","unstructured":"Li L, Han JL, Li HY et al (2012) Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction (abstract). Zhonghua Yi Xue Za Zhi 92:2677\u20132680","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ahj.2008.09.017","volume":"157","author":"JM Siller-Matula","year":"2009","unstructured":"Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148\u2013153","journal-title":"Am Heart J"},{"key":"12_CR44","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa003199","volume":"345","author":"F Canella-Lawson","year":"2001","unstructured":"Canella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooksygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809\u20131817","journal-title":"N Engl J Med"},{"key":"12_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","volume":"108","author":"T Kurth","year":"2003","unstructured":"Kurth T, Glynn RJ, Walker AM et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 108:1191\u20131195","journal-title":"Circulation"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1067\/mcp.2000.110456","volume":"68","author":"N Hergovich","year":"2000","unstructured":"Hergovich N, Aigner M, Eichler HG, Drucker C, Jilma B (2000) Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 68:435\u2013442","journal-title":"Clin Pharmacol Ther"},{"key":"12_CR47","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","volume":"52","author":"JM Siller-Matula","year":"2008","unstructured":"Siller-Matula JM, Lang IM, Christ G, Jilma B (2008) Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52:1557\u20131563","journal-title":"J Am Coll Cardiol"},{"key":"12_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11239-007-0154-1","volume":"27","author":"E Tirnaksiz","year":"2009","unstructured":"Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y (2009) Effect of high dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 27:24\u201328","journal-title":"J Thromb Thrombolysis"},{"key":"12_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1479-5876-6-46","volume":"6","author":"A Kenneth","year":"2008","unstructured":"Kenneth A, Schwartz L, Schwartz DE, Barber K, Reeves M, De Franco AC (2008) Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Trans Med 6:46\u201352","journal-title":"J Trans Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-013-0012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-013-0012-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-013-0012-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-013-0012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T16:14:49Z","timestamp":1548087289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-013-0012-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,9]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s40618-013-0012-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,9]]}}}